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ABSTRACT 1 
Background 2 
The prevalence of tobacco smoking in Germany is high (~27%). Monitoring of national patterns of 3 
smoking behaviour and data on the "real-world" effectiveness of cessation methods are needed to 4 
inform policies and develop campaigns aimed at reducing tobacco-related harm. In England, the 5 
Smoking Toolkit Study (STS) has been tracking such indicators since 2006, resulting in the adaptation 6 
of tobacco control policies. However, findings cannot be directly transferred into the German health 7 
policy context. The German Study on Tobacco Use (DEBRA: "Deutsche Befragung zum 8 
Rauchverhalten") aims to provide such nationally representative data. 9 
 10 
Methods/Study design  11 
In June 2016, the study started collecting data from computer-assisted, face-to-face household 12 
interviews in people aged 14 years and older. Over a period of 3 years, a total of ~36,000 13 
respondents will complete the survey with a new sample of ~2,000 respondents every 2 months 14 
(=18 waves). This sample will report data on demographics and the use of tobacco and electronic (e-15 
)cigarettes. Per wave, about 500-600 people are expected to be current or recent ex-smokers (<12 16 
months since quitting). This sample will answer detailed questions about smoking behaviour, quit 17 
attempts, exposure to health professionals' advice on quitting, and use of cessation aids. Six-month 18 
follow-up data will be collected by telephone.  19 
 20 
Discussion  21 
The DEBRA study will be an important source of data for tobacco control policies, health strategies, 22 
and future research. The methodology is closely aligned to the STS, which will allow comparisons 23 
with data from England, a country with one of the lowest smoking prevalence rates in Europe (18%). 24 
 25 
Trial registration 26 
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This study has been registered at the German Clinical Trials Register (DRKS00011322) on 25th 1 
November 2016. 2 
 3 
Keywords 4 
German Study on Tobacco Use, Epidemiology, Tobacco smoking, E-Cigarette, Household Survey 5 
 6 
 7 
BACKGROUND 8 
 9 
In Germany, 110,000 people die from smoking tobacco each year [1]. In total, 13% of the country's 10 
mortality is attributable to smoking [1]. While the implementation of various tobacco control 11 
policies has led to a reduction in smoking prevalence in high-income countries such as in England 12 
(current prevalence = 18%) [2], the prevalence in the German adult population is still high (27%) [3]. 13 
Like in other countries, smoking prevalence is considerably higher in low income smokers [4, 5], 14 
which results in substantial health inequalities between higher- and lower- income groups [6]. 15 
 16 
Monitoring of national patterns of smoking and quitting behaviour is needed to inform policies and 17 
develop successful campaigns aimed at reducing tobacco-related harm. Relevant parameters to 18 
monitor include: smoking prevalence; rates, duration, trigger and success of quit attempts; exposure 19 
to health professionals' advice on quitting; the use of harm reduction strategies such as "cutting 20 
down"; and the use of cessation aids [7]. Demographic information such as gender or socioeconomic 21 
status (SES) and the influence of potential confounders on the smoking cessation process, e.g., the 22 
motivation to stop or the degree of nicotine dependence, also have to be considered [7]. 23 
 24 
Several national large-scale surveys (ongoing or already completed) [4, 8-10] have been providing 25 
useful data on tobacco consumption and smoking behaviour in Germany, but they all have 26 
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limitations. First, these surveys cover a wide range of addictions and other health topics in general 1 
which means that they do not allow for in-depth analysis of data on smoking behaviour. Second, 2 
these surveys collect data only on an annual or even less frequent basis. Data are therefore often 3 
out of date, and there is a lack of flexibility to adjust survey items to new, specific trends in smoking 4 
behaviour (e.g., the introduction of electronic (e-)cigarettes). This limits their topical relevance for 5 
tobacco control policies and research. Third, the sample sizes of some of these surveys are not 6 
sufficiently large to allow statistically reliable analyses.  7 
 8 
Collection of observational "real-world" data on the effectiveness of smoking cessation methods is 9 
important to supplement randomised controlled trials (RCTs), whose generalisability is somewhat 10 
limited because of the participant selection criteria. There is good evidence from RCTs that 11 
behavioural support and pharmacological treatment, such as nicotine replacement therapy (NRT), 12 
bupropion, or varenicline, improve the success of quit attempts [11-15]. However, analyses on the 13 
real-world effectiveness of smoking cessation methods from the observational Smoking Toolkit 14 
Study (STS) from England [16] showed, for example, that smokers who buy NRT over the counter to 15 
aid their quit attempt have similar odds of success as those who tried to stop unaided [17], 16 
indicating the importance of providing cessation medication together with behavioural support. The 17 
STS is a large ongoing cross-sectional household survey which provides monthly data as well as six-18 
month follow-up data on smoking and cessation behaviour in the English general population aged 16 19 
years and older [16]. Findings from the STS cannot be directly transferred to the German health 20 
policy context. Whereas behavioural support and pharmacological smoking cessation treatment, for 21 
instance, is offered at no or minimal cost in England, such services do not exist in Germany, and 22 
evidence-based treatments are not or only partly reimbursed.  23 
 24 
Moreover, little is known about the real-world effectiveness of e-cigarettes for smoking cessation in 25 
the German population. Its popularity and usage has rapidly increased in recent years. In England, 26 
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for example, the prevalence of "ever-users" (people who used an e-cigarette at least once) in 1 
smokers and recent ex-smokers has increased from approximately 2% in 2011 to approximately 25% 2 
in 2016 [2]. Data from Germany show a comparable trend [3, 18]. Due to design and variety of 3 
flavours, e-cigarettes appear popular among adolescents. Authors have debated whether or not e-4 
cigarettes may facilitate nicotine addiction in this age cohort [19, 20]. Therefore, tracking e-cigarette 5 
usage behaviour in adolescents is of particular importance. 6 
 7 
Aims 8 
The DEBRA study will fill a crucial gap in the literature by collecting up-to-date and in-depth data on 9 
key indicators regarding the patterns and trends of smoking and quitting in the German population, 10 
helping to guide policy and clinical practice. The collection of baseline and follow-up data provides 11 
the possibility for longitudinal analyses on within-individual trends in relevant parameters. These 12 
data can contribute to a better understanding of smoking cessation processes in the general 13 
population and the role played by triggers such as motivation or physician advice, sociodemographic 14 
factors, and aids to cessation such as NRT, behavioural support, or even non-evidence-based 15 
methods, including e-cigarettes. The methodology of DEBRA is closely aligned to the STS, allowing 16 
comparisons with relevant data from the English population. The study design allows a flexible 17 
adjustment of the scope of the survey to address emerging questions relevant to policy changes, 18 
practice or research. 19 
 20 
 21 
METHODS  22 
 23 
Design and Sample 24 
The DEBRA study started in June 2016 to collect data bi-monthly from computer-assisted face-to-25 
face household interviews of people aged 14+. Over a period of 3 years, every two months, a new 26 
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sample of approximately 2,000 respondents will complete the survey (= 18 waves, approximately 1 
36,000 respondents in total). Per wave, about 500-600 people are expected to smoke tobacco or to 2 
be recent ex-smokers (i.e., have smoked in the past 12 months). It is anticipated that data on 3 
approximately 10,000 smokers and recent ex-smokers will be collected during the 3-year period. All 4 
smokers and recent ex-smokers who are willing to be re-contacted will be followed-up at 6 months 5 
following baseline by telephone to complete a short survey. It is expected that about 120-150 (25%) 6 
from each baseline wave will agree to be followed-up, resulting in a total sample size of 7 
approximately 2,500 respondents with baseline and follow-up data. 8 
 9 
The fieldwork is conducted by the market research institute Kantar Health Munich, Germany. The 10 
investigation area is the Federal Republic of Germany. The total population of the study covers all 11 
German speaking persons aged 14 years or over who live in private households during the survey 12 
period. To keep the costs manageable, the baseline survey will use a multi-topic omnibus survey, a 13 
regular series of surveys from Kantar Health to which questions can be added. Per wave up to 280 14 
trained interviewers will conduct on average 7 interviews each. Questions of the DEBRA study are 15 
placed in the middle of the 1 hour multi-topic omnibus survey. 16 
 17 
Baseline data collection will be facilitated through multi-stage, multi-stratified random probability 18 
sampling. Firstly, all communities within Germany will be stratified by the following regional 19 
attributes: federal state (n = 16), administrative districts (a maximum of n = 41 per federal state), 20 
and type of community (a maximum of n = 10 per district). For stratification purposes, these 21 
attributes will be used in combination. Hence, each type of community in every administrative 22 
district builds a different stratum, which theoretically leads to a total of 410, in practice fewer, 23 
strata.  24 
 25 
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To determine the primary sampling units for the study, the geographical area of Germany was 1 
divided into 53,000 small areas of approximately equal size, based on communities, and using 2 
geographic street mapping system software. For each small area, the sample size was determined in 3 
proportion to the total number of households in the area, relative to the total number of households 4 
in the whole population. This is called an area sample or sample point. In the current study the 5 
number of sample points varies between 360 and 410. All small areas were also allocated to their 6 
superordinate geographical units, such as rural and urban districts and municipalities, to allow 7 
further stratification of the sample. Sampling units of the second stage will be represented through 8 
private households and selected by a random walk procedure. Sampling units of the third stage will 9 
be the target persons themselves. These will be selected using a random process (so called 10 
"Schwedenschlüssel"), which gives an equal chance of selection to every eligible person within a 11 
household [21].  12 
 13 
Weighting techniques 14 
Data analyses will take into account weighting adjustments for personal and household 15 
characteristics. According to the multi-stage sampling procedure of baseline data the weighting has 16 
to be done in separate stages, too. One has to differentiate between the so-called design weighting, 17 
which corrects unequal selection probabilities due to the sample design, and the outcome 18 
weighting, which corrects disproportions based on the structure of target persons who did or did not 19 
participate in the survey. Step 1 and step 3 (see further on) are calculated as rim-weighting within an 20 
iterative process. Step 2 is calculated by an analytical approach. 21 
 22 
First step (outcome weighting) 23 
The sampling procedure gives every household the same chance to be selected which means that 24 
the realised sample should be distributed proportionally to the distribution of private households. 25 
Within this first step, the structure of the realised sample is compared to the proportions of the 26 
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original stratification of the first sampling stage. The weighting factors correct differences between 1 
the original and the realised household characteristics. 2 
 3 
Second step (design weighting) 4 
In sampling stage 3 (see below) every eligible person within a household has the same chance of 5 
selection. Hence, the selection probabilities of the target persons differ across the whole sample 6 
according to the size of the household they live in. This unequal selection probability is corrected by 7 
an analytical mathematical procedure using the size of the households. The household sample is 8 
changed into a sample of persons where every respondent has equal selection probability. 9 
 10 
Third step (outcome weighting) 11 
The last weighting step corrects for differences between the demographic structures of the 12 
respondents and the structures of the total population using the following structures: Federal states 13 
combined with sex and generally seven age classes. 14 
 15 
Baseline measures 16 
The main baseline questionnaire for the DEBRA can be found in Additional file 1. To ensure 17 
comparability of data, the majority of questions has been adopted from the STS survey and labelled 18 
appropriately in the questionnaire [16]. STS questions were developed by an expert panel and policy 19 
makers [16]. Existing questions from the STS were translated into German and new questions were 20 
developed by a bilingual team of researchers  ?ƐĞĞĂƵƚŚŽƌƐ ?ĐŽŶƚƌŝďƵƚŝŽŶƐ ? with experience in using 21 
the STS data. Some of the validated scales from the STS were translated and culturally adapted 22 
according to international guidelines [22]. 23 
 24 
Baseline DEBRA questions for each respondent cover smoking status and ever-use of e-cigarettes. 25 
Depending on the response behaviour, current tobacco smokers (cigarettes or other tobacco 26 
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products), recent ex-smokers (<12 months since quitting tobacco) and ever-users of e-cigarettes or a 1 
similar product (e.g., e-hookah, e-cigar, or e-pipe) will answer on further detailed questions about 2 
ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƌ ? ƋƵŝƚ ĂƚƚĞŵƉƚƐ ? ĞǆƉŽƐƵƌĞ ƚŽ ŚĞĂůƚŚ ƉƌŽĨĞƐƐŝŽŶĂůƐ ? ĂĚǀŝĐĞ ŽŶƋƵŝƚƚŝŶŐ ? ĂŶĚ ƵƐĞ ŽĨ3 
cessation aids (Table 1). In addition, socioeconomic data (including age, sex, housing situation, 4 
residential area, marital status, education, respondent and household income, and employment 5 
status) will be regularly collected in all respondents as part of the omnibus survey. 6 
 7 
The study design is flexible. Depending on trends in population usage of tobacco or nicotine 8 
products, in tobacco research, or tobacco control policies, it is intended that new questions can be 9 
added from wave to wave while others will be removed when adequate statistical power is reached 10 
to address a specific scientific issue. 11 
 12 
Six-month follow-up 13 
Smokers and recent ex-smokers who agree to be followed-up will be re-contacted by telephone six 14 
months following baseline. The computer assisted telephone interviews will be performed by 15 
interviewers from Kantar Healths' call centre using a Sample Management System (SMS). The SMS 16 
manages and controls all telephone contacts (e.g., telephone numbers that cannot be contacted are 17 
set deferred, and presented again after a long interval at different times of a day). Interviewers will 18 
try to reach the respondents up to ten times at various times and on different days of the week.  19 
 20 
Additional file 2 shows the main follow-up questionnaire for the DEBRA study. Follow-up questions 21 
focus on current smoking status and on detailed exploration of any quit attempts that have been 22 
made during the past six months. Methods used for a quit attempt (if so) will be asked in 23 
concordance to the baseline survey. This prospective element enables us to further analyse the real-24 
world effectiveness of smoking cessation methods using longitudinal data [23] and providing data on 25 
within-individual trends. The short time frame between baseline and follow-up takes into 26 
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consideration the fact that many smokers make multiple quit attempts within a short space of time 1 
and often rapidly forget unsuccessful ones [24]. Smokers who try to stop unaided, for example, seem 2 
to forget failed quit attempts more quickly than those who use treatment, what might lead to an 3 
underestimation of the effectiveness of stop-smoking medications [25]. 4 
 5 
Main research topics addressed by the DEBRA study 6 
The following research topics will be addressed from the beginning of data collection in wave 1 (June 7 
2016). It is very likely that more topics will be added over time. 8 
 9 
1. Prevalence rates and monitoring of trends 10 
DEBRA will provide prevalence rates and proportions of key parameters on smoking status, smoking 11 
behaviour, quit attempts and their triggers, exposure to health professionals' advice on quitting, and 12 
use of evidence-based as well as non-evidence-based cessation aids, including e-cigarettes, stratified 13 
by socioeconomic factors, nicotine dependence or motivation to quit. Longitudinal analyses from 14 
baseline to follow-up will provide insight into within-individual trends in each of these parameters. 15 
Time series analyses will assess changes including seasonal trends, linear trends, and as a function of 16 
policy changes or media campaigns.  17 
 18 
2. Social gradient in quit attempts and successful abstinence 19 
It is important to determine causes of the higher smoking prevalence rates in disadvantaged groups. 20 
Data from the STS showed that smokers in more deprived socioeconomic groups in England are just 21 
as likely as those in higher groups to try to stop and use aids to cessation [26]. However, there is a 22 
strong gradient across socioeconomic groups in success, with significantly lower success rates in 23 
disadvantaged groups being half as likely to succeed compared with the highest [26]. DEBRA data 24 
will examine to what extent these findings also apply to different socioeconomic groups in Germany.  25 
 26 
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3. External validation of the Motivation to Stop Scale (MTSS)  1 
Smoker's motivation to stop smoking is an important source of information, as it predicts the 2 
incidence of future quit attempts [27, 28]. Moreover, measuring changes in motivation to stop on a 3 
population level is useful to assess and to track the impact of tobacco control policies interventions 4 
over time. For this purpose, the single-item MTSS has been developed as a valid and cost-effective 5 
tool [27]. The MTSS combines key motivational constructs and has been shown to be a strong and 6 
accurate predictor of future quit attempts. With the DEBRA study, we aim to determine the external 7 
validity of the translated and culturally adapted MTSS (MRS: "Motivation zum Rauchstopp Skala") 8 
among German smokers in predicting future quit attempts. 9 
 10 
4. External validation of the Strength of Urges to Smoke Scale (SUTS)  11 
An important criterion for a measure of nicotine dependence is how well it predicts relapse 12 
following smoking cessation. A commonly used scale to assess dependence and predict relapse is the 13 
Fagerström Test for Cigarette Dependence (FTCD) [29]. However, no representative data have been 14 
published on the predictive validity of the FTCD among German smokers. Furthermore, in recent ex-15 
smokers, dependence cannot be measured with the FTCD, as one of its items includes the number of 16 
cigarettes smoked per day. By contrast, the two-item SUTS has been found to be a strong indicator 17 
of the severity of nicotine dependence and to be a better predictor of relapse than the FTCD [30] in 18 
the English population. Its use also allows analyses on the effectiveness of cessation methods (used 19 
during the last quit attempt) in recent ex-smokers through adjusting for urges to smoke as a 20 
confounder [17]. We aim to determine the external validity of the translated and culturally adapted 21 
SUTS (VRS: "Verlangen zu Rauchen Skala") among German smokers and recent ex-smokers in 22 
measuring nicotine dependence and predicting relapse. 23 
 24 
5. Real-world effectiveness of evidence-based and non-evidence-based smoking cessation methods, 25 
including e-cigarettes  26 
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Numerous analyses on the real-world effectiveness of smoking cessation aids have been conducted 1 
with data from the STS in England, for example, to supplement RCT data and to provide estimates 2 
for the effectiveness in the general population [17]. However, transferability of STS results to the 3 
German health policy context is difficult because evidence-based cessation aids are not or only 4 
partly reimbursed in Germany. The DEBRA study will provide such data for Germany. Moreover, 5 
hardly any national data is available on usage and real-world effectiveness of non-evidence-based 6 
methods, including e-cigarettes. In England, for instance, e-cigarettes have already become the most 7 
frequently chosen method of quitting tobacco, possibly contributing to the country's decline in 8 
tobacco smoking [31]. The DEBRA study aims at assessing the emerging role of the e-cigarette as an 9 
aid in smoking cessation in Germany and evaluating its real-world effectiveness to complement 10 
sparse data coming from one existing RCT which found a clinically relevant difference in continuous 11 
6-month abstinence between active vs. placebo e-cigarette users trying to quit [32]. 12 
 13 
6. Factors associated with the use of aids to cessation 14 
Recent data from Germany suggest that only a small proportion of smokers use evidence-based aids 15 
while trying to quit [33]. Most smokers still try to quit unaided, which is associated with high relapse 16 
rates, particularly within the first weeks of abstinence where the strongest withdrawal symptoms 17 
occur [34]. The assessment of differences in sociodemographic or smoking characteristics might 18 
support health strategies to address specific groups of smokers who are underutilising evidence-19 
based cessation aids in health strategies to a greater extent [35]. Therefore, the DEBRA study aims to 20 
analyse variations in use of smoking cessation aids among German smokers trying to quit. 21 
 22 
7. Exposure to health professionals' advice on quitting 23 
Brief advice on smoking cessation delivered by a physician has been found to be effective and 24 
affordable [36, 37]. Hence, clinical practice guidelines recommend implementing brief advice on 25 
smoking cessation into routine primary care to assist a large number of smokers. Nevertheless, these 26 
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recommendations seem to be only rarely implemented into practice in Germany [38] and hardly any 1 
representative and up-to-date data is available on frequency of delivery and approaches used to 2 
deliver such advice. The DEBRA study aims to provide such nationally representative data to inform 3 
policy health strategies aimed at implementing the clinical guidelines.  4 
 5 
Data analysis and sample size calculation 6 
Statistical data analyses depend on scientific issues that will be addressed by the DEBRA study. 7 
Detailed analyses will therefore be reported in the publication of each future study, respectively.  8 
 9 
The methodology of DEBRA is closely aligned to the English STS. Our assumptions about expected 10 
means and variances for the primary analyses are therefore made on the basis of these STS analyses 11 
[17, 23, 39, 40]. Data indicate that, depending on the specific issue, a sample between 1,500 and 12 
7,000 interviewed smokers and recent ex-smokers are needed to yield adequate statistical power of 13 
>80%. The total required sample size was determined considering current prevalence rates of 14 
smokers in Germany [4], available data on rates of cessation attempts within the past 12 months 15 
[33], and physician visits within the past 12 months [41], whereas average response rates at follow-16 
up were estimated by Kantar Health on the basis of previous surveys. During the 18 waves of the 17 
DEBRA study with approximately 2,000 interviews per wave, about 500-600 people are expected to 18 
smoke tobacco or to be recent ex-smokers (in total = ~10,000). Based on these assumptions the 19 
required baseline sample sizes from a total of 1,500 to 7,000 smokers and recent ex-smokers can be 20 
achieved within 3 years. A response rate of 20-25% is expected at follow-up, resulting in a sample 21 
size of approximately 2,500 after 3 years. 22 
 23 
Dissemination of findings 24 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
14 
 
Findings from this survey will be reported in national and international peer-reviewed scientific 1 
journals, and at national and international conferences. Up-to-date statistics will be also published 2 
on the study website: www.debra-study.info. 3 
 4 
 5 
DISCUSSION 6 
 7 
Reducing the prevalence of tobacco smoking is one of the most important strategies for reducing the 8 
burden of morbidity, premature death, and health inequalities between higher and lower income 9 
groups within the next decades [42]. Continuous monitoring of national patterns of smoking and 10 
quitting behaviour as well as real-world data on the effectiveness of smoking cessation methods are 11 
needed to guide tobacco control policies and clinical practice.  12 
 13 
The DEBRA study aims to provide such representative data for Germany. Its methodology is 14 
sufficiently flexible to allow adaptions of its research scope and tracking data on every two months 15 
permits a much more sensitive test of the possible effects of interventions than can be achieved by 16 
annual national surveys. Hence, DEBRA data will provide quick and direct estimates of policy or 17 
health strategy impacts aimed at reducing tobacco-related harm as well as of its cost-effectiveness.  18 
 19 
The results of the DEBRA study can also be relevant to improve clinical care for smokers. Real-world 20 
data on the effectiveness of smoking cessation aids might complement the current state of 21 
knowledge on evidence-based and non-evidence-based smoking cessation processes which is usually 22 
obtained from RCTs. Data on prevalence of the use of such methods and on exposure to health 23 
professionals' advice on quitting might help to analyse the as-is state of usage and care. Future 24 
interventional studies might then address discrepancies between the as-is (e.g., under-usage of 25 
evidence-based treatments to aid cessation) and the target state of use (e.g., use of evidence-based 26 
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treatments). Such interventions could address both, the physicians and the patients themselves, to 1 
increase rates of recommendations as well as the use of evidence-based cessation aids.  2 
 3 
We expect the DEBRA methodology to be robust and reliable. However, data from the first waves 4 
will have to be analysed to compare the representativeness of the DEBRA data to other ongoing 5 
national large scale surveys [4, 8-10]. Slight deviations can certainly occur due to different modes of 6 
data collection (face-to-face interview, telephone, or online), seasonal fluctuations, differences in 7 
weighting procedures, as well as differences due to the inclusion of diverse age groups of 8 
participants. 9 
 10 
There are certain general limitations that apply to large national surveys such as the DEBRA study, 11 
including those associated with self-report which may be biased or inaccurate. Furthermore, drop-12 
out rates from baseline to six month follow-up are expected to be substantial and possibly 13 
differential. However, representativeness of the follow-up samples will be examined in detail by 14 
comparisons with baseline data on key variables from those not followed up and results from such 15 
analyses will be interpreted accordingly. Finally, even if the DEBRA study aims to collect a sample of 16 
smokers large enough to yield adequate statistical power for several subgroup analyses, certain 17 
analyses are likely to be underpowered due to small sample sizes, e.g. in relation to ethnicity, 18 
specific professions, or usage of specific e-inhalation products (e.g., e-hookah, e-cigar, or e-pipe).  19 
 20 
Conclusions 21 
The DEBRA study will enhance understanding of factors influencing smoking and cessation behaviour 22 
on a population level and be an important resource of scientific data for the development of tobacco 23 
control policies, health strategies, and future studies in Germany. The study design allows a flexible 24 
adjustment of the scope of the survey to specific trends in smoking behaviour, topical questions in 25 
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tobacco research or policies. The methodology of the study is closely aligned to the STS, allowing 1 
international comparisons of data.  2 
 3 
List of abbreviations 4 
DEBRA = German Study on Tobacco Use ("Deutsche Befragung zum Rauchverhalten") 5 
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MTSS = Motivation to Stop Scale 9 
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SUTS = Strength of Urges to Smoke Scale 15 
 16 
 17 
DECLARATIONS 18 
 19 
Ethics approval and consent to participate 20 
The study protocol has been peer-reviewed and approved by the ethics committee of the Heinrich-21 
Heine-University Duesseldorf, Germany (ID 5386/R). The fieldwork is conducted by the market 22 
research institute Kantar Health Munich, Germany. The interviewers from Kantar Health make sure 23 
that all participants give oral informed consent. This method of consent has been also approved by 24 
the ethics committee.     25 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
17 
 
 1 
Consent to publish 2 
Not applicable. 3 
 4 
Availability of data and materials 5 
Data sharing is not applicable to this article as this is a study protocol.  6 
 7 
Competing interests 8 
SK, LSB and CCB have no conflict of interest to declare. JB has received unrestricted research funding 9 
from Pfizer, who manufacture smoking cessation medications. LS has received honoraria for talks, an 10 
unrestricted research grant and travel expenses to attend meetings and workshops from Pfizer, and 11 
has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care 12 
companies. RW has undertaken research and consultancy for companies that develop and 13 
manufacture smoking cessation medications (Pfizer, Johnsons & Johnson, and Glaxo Smith Kline). He 14 
is an advisor to the UK's National Centre for Smoking Cessation and Training. His salary is funded by 15 
Cancer Research UK. DN is a member of the advisory board of Pfizer and has received travel grants 16 
and honorarium. TR has received honoraria from Pfizer, Novartis, Glaxo Smith Kline, Astra Zeneca 17 
and Roche as a speaker in activities related to continuing medical education. He has also received 18 
financial support for investigator-initiated trials from Pfizer and Johnson & Johnson. DK received an 19 
unrestricted grant from Pfizer in 2009 for an investigator-initiated trial on the effectiveness of 20 
practice nurse counselling and varenicline for smoking cessation in primary care (Dutch Trial Register 21 
NTR3067). 22 
 23 
Funding 24 
The study is funded by the Ministry for Innovation, Science and Research of the German Federal 25 
State of North Rhine-Westphalia ("NRW-Rückkehrprogramm") who had no involvement in the 26 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
18 
 
design of the study, the collection, analysis, and interpretation of data, or in the writing of the 1 
manuscript. 2 
 3 
ƵƚŚŽƌƐ ?ĐŽŶƚƌŝďƵƚŝŽŶƐ 4 
DK acquired funding for the current study. DK and SK lead the study processes including data 5 
collection, data analyses, and the development of new questions for the DEBRA interview guide 6 
together with DN. SK and DK developed and co-wrote the study protocol. The team from the English 7 
Smoking Toolkit Study (STS) RW, JB, LSB, ER, TR and LS developed the study design of the STS to 8 
which the design of the DEBRA study is closely aligned. LSB, ER, TR, DK and LS were part of the 9 
bilingual team which translated the STS questionnaire into German. CCB holds a major part in 10 
describing the methodological aspects of the data collection conducted by Kantar Health. All named 11 
authors contributed substantially to the manuscript and agreed on its final version. 12 
 13 
Acknowledgements 14 
We would like to thank Reiner Hanewinkel for his feedback on the early drafts of the baseline 15 
questionnaire. 16 
 17 
Additional files 18 
Additional file 1: DEBRA - Baseline survey (.docx 67 kb).  19 
Additional file 2: DEBRA - Follow-up survey.docx (.docx 38 kb)  20 
21 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
19 
 
Table 1. Content of the baseline questionnaire for current smokers, recent ex-smokers, and e-1 
cigarette users 2 
Current smokers and 
recent ex-smokers 
1. Current smoking behaviour (or past smoking behaviour in 
those that have recently stopped) 
2. Current motivation to quit smoking using the Motivation to 
Stop Scale [27] 
3. Use of nicotine replacement therapy while smoking 
4. Current (or past) nicotine dependence using the Fagerström 
Test for Cigarette Dependence [29] 
5. Exposure to health professionals' advice on quitting 
6. Current (or past) strength of urges to smoke [30] 
7. The number of serious quit attempts recalled as having been 
made within the past 12 months 
8. For the most recent quit attempt within the past 12 months:  
a. how long-ago the quit attempt started 
b. how long it lasted 
c. any aids used (e.g., nicotine replacement therapy over-the-
counter, telephone helpline) 
d. what triggered it (external and internal triggers) 
e. whether it involved cutting down gradually 
f. and whether it was planned in advance [7] 
E-cigarette users 
1. Usage behaviour and its development 
2. Starting age and reasons for e-cigarette use 
3. Type, place of purchase and average consumption of liquid 
and nicotine in e-cigarettes 
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